Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AKR.L (AKR) Share News

12345

Akers Biosciences Inks Sales And Distribution Agreement With Typenex

4th Jun 2014 11:11

LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it had inked a sales and distribution agreement with Typenex Medical LLC for its PIFA Heparin/PF4 and PIFA PLUSS Platelet Factor 4 test kits. Akers said that the agreement was part of its strategy to accelerate sales of the Read More

UK MORNING BRIEFING: Tesco Reports Sales Decline Amid Price Cutting

4th Jun 2014 07:25

LONDON (Alliance News) - UK shares have opened mostly lower, with small-caps slightly outperforming Wednesday ahead of the Queen's Speech and further European economic data.<br /><br />Starting the trading day on a negative note, <strong>Tesco</strong> PLC reported a sharp drop in sales in the Read More

Akers Biosciences Inks India Marketing Agreement With Jai Capital

16th May 2014 11:33

LONDON (Alliance News) - Akers Biosciences Inc said Friday that it had inked an agreement with Nevada-based Jai Capital LLC to market its rapid test products in India. Under the agreement Jai will market Aker's PIFA Heparin/Platelet Factor-4 Rapid Assay test for thrombosis, its PIFA Dengue Read More

Akers Biosciences Profit Hit By IPO Costs, But Revenue More Than Doubles

14th May 2014 11:14

LONDON (Alliance News) - Akers Biosciences Inc, which recently listed on Nasdaq, Wednesday reported a first-quarter net loss of USD595,600, mainly due to the costs of the initial public offering. The maker of rapid diagnostic screening and testing products, which is also listed on London's Read More

Akers Biosciences Adds New Distributor For Diseases Tests

7th May 2014 11:19

LONDON (Alliance News) - Akers Biosciences Inc Wednesday said it had signed a deal whereby Dubai-based Thirty Six Strategies General Trading LLC will sell Akers' infectious diseases tests exclusively for the next three years in some countries. In a statement, Akers said the exclusive agreem Read More

Akers Biosciences Begins Trial For Chlamydia Assay

30th Apr 2014 14:19

LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it has begun clinical trials in the US for its PIFA PLUSS chlamydia assay, a test for chlamydia diagnosis using a finger stick blood sample. The study will include 200 to 250 patients in total, including normal, newly infect Read More

Akers Biosciences Loss Narrows As Breathalysers Boost Revenues

28th Mar 2014 12:38

LONDON (Alliance News) - Akers Biosciences Inc Friday posted a narrowed pretax loss for 2013, as it saw revenues more than double, driven by sales of its breathalyser products, and expressed confidence for 2014 following its dual listing in New York in January. The company posted a pretax l Read More

Akers Biosciences CEO To Step Down

12th Mar 2014 17:23

LONDON (Alliance News) Akers Biosciences Wednesday said Chief Executive Thomas Nicolette will step down from the board and leave the company on March 28. Nicolette, who has been at the helm since 2008, will be replaced by Executive Chairman Raymond Akers. The stock closed at 340.00 pe Read More

UK MIDDAY BRIEFING: Bank Of England Now Focused On Productivity

24th Jan 2014 12:41

LONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.<br /><br />In a speech at the World Ec Read More

UK WINNERS & LOSERS: Cairn Falls As Indian Tax Department Gets In Touch

24th Jan 2014 10:58

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Weir Group, up 0.2%. The engineering company said it had won a USD98 million, or GBP59 million, two-year contract to provide Read More

Akers Bioscience To Recommence Trading On AIM, Prices Offering

23rd Jan 2014 18:16

LONDON (Alliance News) - Akers Biosciences Inc said Thursday that its shares will recommence trading on AIM Friday, and announced the pricing of its public offering on the NASDAQ. Akers Biosciences will offer 2.7 million shares at USD5.50 each, hoping to raise around USD15 million in gross Read More

UK WINNERS & LOSERS: Aberdeen And Lloyds Jump On Scottish Widows Investment Partnership Deal

18th Nov 2013 12:13

Read More

Akers Biosciences To Convert Preferred Shares, Consolidate Shares Ahead Of NASDAQ Listing

18th Nov 2013 11:02

Read More

Akers Narrows Nine Month Pretax Losses As Revenues Rise

15th Nov 2013 14:55

Read More

12345
FTSE 100 Latest
Value8,809.74
Change53.53